Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

FDA Approves Corticosteroid Drug to Treat Duchenne Muscular Dystrophy

XTALKS VITALS NEWS

DMD

The drug has been approved to treat the rare genetic disorder in patients five years of age and older.

Share this!

February 13, 2017 | by Sarah Hand, M.Sc.

Just months after Sarepta Therapeutics’ Exondys 51 became the first US Food and Drug Administration (FDA) approved drug to treat Duchenne muscular dystrophy (DMD), the agency has approved Marathon Pharmaceuticals’ Emflaza (deflazacort). The drug has been approved to treat the rare genetic disorder in patients five years of age and older.

DMD is a disease characterized by progressive muscle weakness and deterioration, which primarily affects young boys. Emflaza is a corticosteroid designed to reduce inflammation and dampen the actions of the immune system. While corticosteroids are already in use for the treatment of DMD in other countries, the approval of Emflaza marks the first corticosteroid approval for this indication in the US.

“This is the first treatment approved for a wide range of patients with Duchenne muscular dystrophy,” said Dr. Billy Dunn, director of the Division of Neurology Products in the FDA's Center for Drug Evaluation and Research. “We hope that this treatment option will benefit many patients with DMD.”

A clinical trial involving 196 male patients between the ages of five and 15 years old was conducted to assess the effectiveness of deflazacort. All patients had a confirmed mutation in the dystrophin gene, the protein product of which is responsible for stabilizing muscle fibers.

After 12 weeks of being treated with deflazacort, the DMD patients saw improvements in muscle strength, compared to those taking the placebo. According to the FDA, patients on deflazacort also lost the ability to walk later compared to the placebo group, although this result was not statistically controlled for multiple comparisons.



“Today we celebrate FDA approval of Emflaza as a treatment option for kids and adults living with Duchenne muscular dystrophy,” said Steven M. Derks, President and CEO of the Muscular Dystrophy Association (MDA). “This approval follows decades of MDA research — including early-stage development and testing of Emflaza in DMD patients — that was made possible by the hard work, dedication and unwavering commitment of our donors and sponsors.

“Drugs like Emflaza aren't developed in silos, but rather through the combined efforts of biotechs and drug companies, patient organizations like MDA, corporate partners and donors, and the families who are there every step of the way to see it through. We are grateful to be part of such a welcome new development in the DMD landscape — and, more importantly, to belong to such a giving and dedicated community.”

In September of 2016, Exondys 51 became the first drug to be approved to treat DMD. Just three months later, the FDA approved Spinraza for the treatment of spinal muscular atrophy, another rare neuromuscular disease.


Keywords: FDA, Duchenne Muscular Dystrophy, Corticosteroids


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Food Companies are Looking for the Next Sriracha

October 19, 2017 - The Sriracha trend might be coming to an end and companies are looking for the next big hot sauce star to feature in their line-up.

Featured In: Food News


CFIA Recalling Mechanically Tenderized Steaks in Canada for E. coli

October 19, 2017 - The Canadian Food Inspection Agency posted a recall for mechanically tenderized steaks at the request of Vantage Foods Inc. on Tuesday.

Featured In: Food News


Study: Gender May Be Important When Matching Blood Transfusion Recipients to Donors

October 19, 2017 - According to a new study published in JAMA, gender and a history of pregnancy among female donors may have an impact on how well blood donors and recipients can be matched.

Featured In: Life Science News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Five Reasons Why Toronto is Emerging as a Major Life Sciences Hub

REGISTER FOR THESE WEBINARS

Brexit – Separating Fact from Fiction


Evolving Best Practices for Working with Authors of Scientific Publications – Authorship and Beyond


Human Whole-Genome Sequencing in a New Era Defined by the Illumina® HiSeq X® and NovaSeq™ Platforms


Clinical Event Adjudication: Comprehensive and Efficient Dossier Review Using a Global On-Line Solution


Copyright © 2016-2017 Honeycomb Worldwide Inc.